Attached files
| file | filename |
|---|---|
| 8-K - CALADRIUS BIOSCIENCES, INC. | v202889_8k.htm |
| EX-3.1 - CALADRIUS BIOSCIENCES, INC. | v202889_ex3-1.htm |
| EX-1.2 - CALADRIUS BIOSCIENCES, INC. | v202889_ex1-2.htm |
| EX-4.1 - CALADRIUS BIOSCIENCES, INC. | v202889_ex4-1.htm |
| EX-5.1 - CALADRIUS BIOSCIENCES, INC. | v202889_ex5-1.htm |
| EX-1.1 - CALADRIUS BIOSCIENCES, INC. | v202889_ex1-1.htm |
| EX-4.2 - CALADRIUS BIOSCIENCES, INC. | v202889_ex4-2.htm |
| EX-10.2 - CALADRIUS BIOSCIENCES, INC. | v202889_ex10-2.htm |
| EX-10.1 - CALADRIUS BIOSCIENCES, INC. | v202889_ex10-1.htm |
NeoStem
Announces Pricing of Concurrent
Offerings
for $19 Million in Gross Proceeds
NEW YORK,
Nov 16 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or
the "Company") an international biopharmaceutical company with product and
service revenues, global research and development capabilities and operations in
three distinct business units, U.S. adult stem cells, China adult stem cells,
and China pharmaceuticals today announced the pricing of concurrent
offerings.
An
underwritten registered offering of 6,337,980 common units at $1.45 per
unit. Each unit consists of one share of common stock and a warrant
to purchase 0.5 of a share of common stock with a per share exercise price of
$1.85. Cowen and Company, LLC acted as sole book-running manager and
Maxim Group LLC and National Securities Corporation acted as co-managers for
this offering.
A
registered direct offering of 10,582,011 preferred units. Each unit consists of
one share of series E 7% senior convertible preferred stock convertible at
$2.0004, maturing May 20, 2013, a warrant to purchase 0.25 of a share of
common stock with a per share exercise price of $2.0874 and 0.0155 shares of
common stock. Cowen and Company, LLC and LifeTech
Capital, a division of Aurora Capital LLC, acted as co-placement agents for
this offering.
From the
two offerings, which are running concurrently, the company expects to receive
$19 million in gross proceeds, prior to deducting underwriting discounts
and commissions, placement agent fees and offering expenses payable by the
company. These funds will give Neostem the ability to proceed with
its acquisition of Progenitor Cell Therapy LLC, and focus on growing the cord
blood and adult stem cell banking, cellular manufacturing and therapeutic
business, as well as expand our businesses in Asia and other countries.
Additionally, the company will be able to continue to develop its intellectual
property and acquire new technology. $2,500,000 will be placed in
escrow pursuant to the terms of the offering.
The
transactions are expected to close on or about November 19, 2010, subject to the
satisfaction of customary closing conditions.
Each of
these offerings is being made only by means of a prospectus supplement and
accompanying prospectus. Copies of the final prospectus
supplement and accompanying prospectus relating to each of these offerings may
be obtained from the Securities and Exchange Commission’s website at
http://www.sec.gov or from the offices of Cowen and Company, LLC (c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn:
Prospectus Department (631) 254-7106).
A shelf
registration statement relating to each of these offerings has previously been
filed with the Securities and Exchange Commission and which became effective on
May 11, 2010. This press release is neither an offer to sell nor a
solicitation of an offer to buy any of the Company’s securities. No
offer, solicitation or sale will be made in any jurisdiction in which such
offer, solicitation or sale is unlawful.
Further
information regarding the offerings is contained in the Company’s Current Report
on Form 8-K to be filed with the Securities and Exchange Commission and which
may be accessed at www.sec.gov.
About
NeoStem, Inc.
NeoStem,
Inc. is engaged in the development of stem cell-based therapies, pursuit of
anti-aging initiatives and building of a network of adult stem cell collection
centers in the U.S. and China that are focused on enabling people to donate and
store their own (autologous) stem cells for their personal use in times of
future medical need. The Company also has licensed various stem cell
technologies, including a worldwide exclusive license to VSEL™ Technology which
uses very small embryonic-like stem cells, shown to have several physical
characteristics that are generally found in embryonic stem cells, and is
pursuing the licensing of other technologies for therapeutic use. NeoStem's
majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures
and distributes generic antibiotics in China. For more information, please
visit: http://www.neostem.com
.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
reflect management's current expectations, as of the date of this press release,
and involve certain risks and uncertainties. Forward looking statements include
statements herein with respect to the successful execution of the Company's
strategy, accelerating Erye's sales growth in 2010 and successful transfer of
Erye's production lines to the new facility, growth in revenues from the
Company's China operations, as well as other advances in the Company's business,
about which no assurances can be given. The Company's actual results could
differ materially from those anticipated in these forward-looking statements as
a result of various factors. Factors that could cause future results to
materially differ from the recent results or those projected in forward-looking
statements include the "Risk Factors" described in the Company's Annual Report
on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010
as well as other periodic filings made with the Securities and Exchange
Commission. The Company's further development is highly dependent on future
medical and research developments and market acceptance, which is outside its
control.
|
For
more information, please contact:
|
|
NeoStem,
Inc.
|
|
Robin
Smith, CEO
|
|
Phone:
+1-212-584-4174
|
|
Email: rsmith@neostem.com
|
|
Web: http://www.neostem.com
|